Skip to main content
. 2014 Mar 1;30(3):272–277. doi: 10.1089/aid.2013.0162

Table 1.

Subject Characteristics

  5152s baseline 5152s week 24 IU on drug IU not on drug
N 82 79 49 47
Age, years (mean) 35.6±8.3 40.3±8.1 37.0±11.5
Male sex 76 (92%) 32 (65%) 38 (81%)
Race/ethnicity
 White non-Hispanic 45 (55%) 28 (57%) 28 (60%)
 Hispanic 12 (15%) 4 (8%) 1 (2%)
 Black 23 (28%) 17 (35%) 18 (38%)
 Unknown 2 (2%)    
Time on ART 24 weeks 39.6±29.5 months [46]
BMI, kg/m2 25.1 (22.8–27.7) [77] 26.0 (23.5–28.4) [73] 25.5 (21.7–28.6) [48] 25.3 (22.4–28.0) [47]
HOMA-IR 1.37 (0.78–2.33) [73] 1.42 (0.02–2.18) [73] 2.29 (1.60–2.76) [43] 2.39 (1.96–3.41) [44]
Total cholesterol, mg/dl 144 (128–163) [81] 180 (159–217) [79] 182 (164–221) [43] 155 (136–169) [44]
Triglycerides 113 (90–178) [81] 177 (100–275) [79] 129 (85–182) [48] 99 (77–157) [47]
HDL cholesterol 31 (26–36) [80] 41 (34–50) [76] 47 (35–55) [45] 38 (28–45) [45]
LDL cholesterol 88 (66–102) [78] 96 (81–118) [68] 104 (90–132) [45] 95 (72–110) [44]
HDL particles, nmol/liter 22.7 (19.9–26.1) [80] 29.0 (25.2–33.2) [76] 25.6 (22.8–28.8) [49] 23.1 (19.5–26.3) [44]
Large HDL particles 3.2 (2.0–4.9) [80] 4.2 (1.6–7.3) [76] 4.1 (2.0–7.3) [49] 3.4 (1.8–4.4) [44]
LDL particles 1124 (874–1298) [80] 1268 (995–1602) [76] 1103 (881–1317) [49] 1060 (821–1352) [44]
CD4+ cells/mm3 245 (119–356) [78] 376 (252–557) [79] 464 (368–735) [48] 335 (218–546) [47]
Log10 HIV RNA copies/ml 4.93±0.63 [82] 1.95±0.74 [79] 2.85±0.72 [46] 4.22±1.00 [44]
% HIV RNA <400 copies/ml 0 [82] 92 [79] 85 [46] 9 [44]
sCD14 (106 pg/ml) 2.12 (1.81–2.57) [82] 2.08 (1.60–2.55) [79] *p=0.4 1.67 (1.53–1.97) [49] 1.68 (1.38–2.03) [42]
LPS (pg/ml) 28.8 (16.5–42.0) [82] 35.1 (17.8–56.6) [79] *p=0.02 27.6 (17.4–38.8) [47] 21.4 (12.9–30.2) [40]
*

p-value for the change from baseline to week 24.

Values are mean±SD or median (25–75% percentile). Numbers in brackets represent the number of subjects who had that variable measured.

ART, antiretroviral therapy; sCD14, soluble CD14; LPS, lipopolysaccharide; IU, Indiana University; BMI, body mass index; HOMA-IR, homeostasis model assessment-insulin resistance; HDL, high-density lipoprotein; LDL, low-density lipoprotein.